Last reviewed · How we verify
Xalatan+Cosopt
Xalatan+Cosopt is a Prostaglandin analog + carbonic anhydrase inhibitor + beta-blocker combination Small molecule drug developed by University of Turin, Italy. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.
This combination reduces intraocular pressure by combining a prostaglandin analog (latanoprost) that increases uveoscleral outflow with a carbonic anhydrase inhibitor and beta-blocker (dorzolamide/timolol) that decrease aqueous humor production.
Xalatan (latanoprost 0.005%) and Cosopt (dorzolamide 2%/timolol maleate 0.5% fixed combination) are medications used to treat conditions such as open-angle glaucoma and ocular hypertension. They are small molecule drugs that work through different mechanisms, with Xalatan likely acting as a prostaglandin analog and Cosopt acting as a carbonic anhydrase inhibitor and beta-adrenergic receptor blocker.
At a glance
| Generic name | Xalatan+Cosopt |
|---|---|
| Sponsor | University of Turin, Italy |
| Drug class | Prostaglandin analog + carbonic anhydrase inhibitor + beta-blocker combination |
| Target | Prostaglandin F receptor (FP receptor); carbonic anhydrase II; beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Xalatan (latanoprost) is a prostaglandin F analog that enhances uveoscleral drainage of aqueous humor. Cosopt (dorzolamide/timolol) combines dorzolamide, a topical carbonic anhydrase inhibitor that reduces aqueous humor secretion, with timolol, a non-selective beta-blocker that also decreases aqueous humor production. Together, these agents work synergistically through multiple mechanisms to lower intraocular pressure.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation/discomfort
- Increased iris pigmentation
- Eyelash growth
- Ocular surface disease
- Headache
- Systemic beta-blocker effects (bradycardia, fatigue)
Key clinical trials
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
- Circadian Rhythms of Aqueous Humor Dynamics in Humans (PHASE2)
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma (PHASE4)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (PHASE4)
- The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xalatan+Cosopt CI brief — competitive landscape report
- Xalatan+Cosopt updates RSS · CI watch RSS
- University of Turin, Italy portfolio CI
Frequently asked questions about Xalatan+Cosopt
What is Xalatan+Cosopt?
How does Xalatan+Cosopt work?
What is Xalatan+Cosopt used for?
Who makes Xalatan+Cosopt?
What drug class is Xalatan+Cosopt in?
What development phase is Xalatan+Cosopt in?
What are the side effects of Xalatan+Cosopt?
What does Xalatan+Cosopt target?
Related
- Drug class: All Prostaglandin analog + carbonic anhydrase inhibitor + beta-blocker combination drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor); carbonic anhydrase II; beta-adrenergic receptors
- Manufacturer: University of Turin, Italy — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing